SOURCE: The Bedford Report

The Bedford Report

April 18, 2011 08:16 ET

Young Biotech Firms Seek Long Term Relevance

The Bedford Report Provides Analyst Research on Vivus and Avanir Pharmaceuticals

NEW YORK, NY--(Marketwire - Apr 18, 2011) - There is plenty of optimism surrounding the biotech sector as firmer pricing and new products have improved sales and earnings trends. Meanwhile, younger, more speculative firms continue to garner significant attention with potential blockbuster products working their way through the regulatory process. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Vivus, Inc. (NASDAQ: VVUS) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Access to the full company reports can be found at:

www.bedfordreport.com/2011-04-VVUS

www.bedfordreport.com/2011-04-AVNR

IMS Health, a leading research and analytical firm serving the pharmaceutical and medical industries, projects an increase in worldwide biotech growth in 2011 of between 5 and 7 percent, with a similar outlook stretching out to 2015. Emerging markets such as China, India, and Brazil are expected to contribute significantly to this growth. Sales growth of 15 percent is forecast in emerging markets, many of which are benefitting from increased government spending on healthcare and broader private health coverage for workers.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Earlier this month shares of Vivus surged after the company released a study that may prompt US regulators to approve its weight loss drug, Qnexa. According to research presented at the American College of Cardiology meeting in New Orleans, Vivus's once-daily pill helped people reduce dependence on blood pressure pills and decrease their triglycerides.

In October the FDA declined to approve Qnexa and asked for more study results and additional information about possible health risks, including major cardiovascular events. The FDA also has said new clinical trials might not be required to satisfy a request for more information about the drug or for it to eventually gain approval.

Also this month Avanir Pharmaceuticals filed an Investigational New Drug application with the Food and Drug Administration to begin a Phase II trial for its investigational drug, AVP-923, in the treatment of central neuropathic pain in patients with multiple sclerosis.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer.

Contact Information